Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    Ruby Khatun Khatun
    Ruby Khatun Khatun
      • Home
      • Ruby Khatun Khatun

      Articles By : Ruby Khatun Khatun

      Merck

      Merck's cancer drug Keytruda notches another trial success

      Ruby Khatun Khatun25 May 2018 9:30 AM IST
      Merck & Co said its drug Keytruda helped patients with a certain type of lung cancer live longer and prevented the disease from spreading, helping...
      Potential malfunction: Abbott recalling HeartMate 3 Left Ventricular Assist System, says USFDA

      Potential malfunction: Abbott recalling HeartMate 3 Left Ventricular Assist System, says USFDA

      Ruby Khatun Khatun24 May 2018 3:17 PM IST
      The US Food and Drug Administration (FDA) announced Abbott is recalling the HeartMate 3™ Left Ventricular Assist System. The FDA said it has...
      Rs 4 lakh fine on AstraZeneca, 3 ex-officials

      Rs 4 lakh fine on AstraZeneca, 3 ex-officials

      Ruby Khatun Khatun24 May 2018 3:15 PM IST
      New Delhi: Markets regulator, SEBI on Wednesday imposed a total penalty of Rs 4 lakh on AstraZeneca PharmaIndia and its three former senior officials...
      Fortis shareholders vote out Brian Tempest from Board

      Fortis shareholders vote out Brian Tempest from Board

      Ruby Khatun Khatun24 May 2018 1:25 PM IST
      New Delhi: Fortis Healthcare said its shareholders have voted in favour of removal of Brian Tempest from the Board of Directors in the company's...
      Sun Pharma gets USFDA nod for prostate cancer drug

      Sun Pharma gets USFDA nod for prostate cancer drug

      Ruby Khatun Khatun24 May 2018 11:00 AM IST
      New Delhi: Drug major Sun Pharmaceutical Industries' subsidiary has received approval from the US health regulator for YONSA, used for the treatment...
      Pfizer Inc recalls 1.8 million vials of antibiotics

      Pfizer Inc recalls 1.8 million vials of antibiotics

      Ruby Khatun Khatun24 May 2018 10:30 AM IST
      New Delhi: Pfizer Inc has recalled over 1.8 million vials of piperacillin and tazobactam, that were manufactured in India, from the US...
      Dr Reddys Labs Q4 net falls 3 percent to Rs 302 crore

      Dr Reddy's Labs Q4 net falls 3 percent to Rs 302 crore

      Ruby Khatun Khatun24 May 2018 9:45 AM IST
      New Delhi: Drug firm Dr Reddy's Laboratories reported a 3.29 percent fall in its consolidated net profit to Rs 302.2 crore for the fourth quarter...
      Suven Life gets product patents from New Zealand, Norway

      Suven Life gets product patents from New Zealand, Norway

      Ruby Khatun Khatun24 May 2018 9:30 AM IST
      New Delhi: Suven Life Sciences said it has been granted a product patent by New Zealand and Norway each corresponding to a new chemical entity (NCE)...
      Labelling norms for high-risk medicines made Stringent, Check out details

      Labelling norms for high-risk medicines made Stringent, Check out details

      Ruby Khatun Khatun23 May 2018 4:59 PM IST
      The new rules will be applicable to medicines such as Narcotic analgesics, hypnotics, sedatives, tranquillizers, corticosteroids, hormones,...
      Fortis: Sebi probes insider trading violation, other regulatory lapses

      Fortis: Sebi probes insider trading violation, other regulatory lapses

      Ruby Khatun Khatun23 May 2018 10:30 AM IST
      New Delhi: Regulator Sebi is probing suspected insider trading by some institutional investors and other regulatory lapses at Fortis Healthcare amid a...
      Cipla posts Q4 net profit at Rs 153 crore

      Cipla posts Q4 net profit at Rs 153 crore

      Ruby Khatun Khatun23 May 2018 10:15 AM IST
      New Delhi: Drug major Cipla reported a consolidated net profit of Rs 153.25 crore for the quarter ended March 31, 2018, mainly on account of robust...
      Glenmark Pharma submits application for new drug Ryaltris with USFDA

      Glenmark Pharma submits application for new drug Ryaltris with USFDA

      Ruby Khatun Khatun23 May 2018 10:00 AM IST
      New Delhi: Glenmark Pharmaceuticals has submitted a new drug application with the US health regulator for its nasal spray Ryaltris.Ryaltris is for...
      PrevNext

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok